Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 8, 2014, 75 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $294.00 to $12,417,450.00.

Highlighted Stocks Traded by Insiders:

GenMark Diagnostics (GNMK) - FREE Research Report

Hawkins Jeffrey Alan, who is SVP, Global Marketing & PM at GenMark Diagnostics, sold 1,350 shares at $12.06 on Dec. 8, 2014. Following this transaction, the SVP, Global Marketing & PM owned 101,003 shares meaning that the stake was reduced by 1.32% with the 1,350-share transaction.

Williams Jennifer Anne, who is SVP, Human Resources at GenMark Diagnostics, sold 1,815 shares at $12.06 on Dec. 8, 2014. Following this transaction, the SVP, Human Resources owned 179,072 shares meaning that the stake was reduced by 1% with the 1,815-share transaction.

Gleeson Michael, who is SVP, North American Com. Ops. at GenMark Diagnostics, sold 1,560 shares at $12.06 on Dec. 8, 2014. Following this transaction, the SVP, North American Com. Ops. owned 174,716 shares meaning that the stake was reduced by 0.88% with the 1,560-share transaction.

The shares most recently traded at $12.99, up $0.93, or 7.16% since the insider transaction. Historical insider transactions for GenMark Diagnostics go as follows:

  • 4-Week # shares sold: 871
  • 12-Week # shares sold: 7,225
  • 24-Week # shares sold: 28,476

The average volume for GenMark Diagnostics has been 195,300 shares per day over the past 30 days. GenMark Diagnostics has a market cap of $541.7 million and is part of the health care sector and health services industry. Shares are down 2.78% year-to-date as of the close of trading on Monday.

GenMark Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, sells, and supports instruments and molecular tests based on its proprietary eSensor detection technology in the United States. Currently, there are 3 analysts who rate GenMark Diagnostics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GNMK - FREE

TheStreet Quant Ratings

rates GenMark Diagnostics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full

GenMark Diagnostics Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Rand Logistics (RLOG) - FREE Research Report

Levy Edward, who is CEO & President at Rand Logistics, bought 4,400 shares at $4.44 on Dec. 8, 2014. Following this transaction, the CEO & President owned 451,349 shares meaning that the stake was boosted by 0.98% with the 4,400-share transaction.

The shares most recently traded at $4.39, down $0.05, or 1.14% since the insider transaction. Historical insider transactions for Rand Logistics go as follows:

  • 4-Week # shares bought: 25,600
  • 12-Week # shares bought: 25,600
  • 24-Week # shares bought: 25,600

The average volume for Rand Logistics has been 37,500 shares per day over the past 30 days. Rand Logistics has a market cap of $79.1 million and is part of the services sector and transportation industry. Shares are down 24.7% year-to-date as of the close of trading on Monday.

Rand Logistics, Inc., through its subsidiaries, provides bulk freight shipping services in the Great Lakes region. The company offers domestic port-to-port services. Currently, there is 1 analyst who rates Rand Logistics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RLOG - FREE

TheStreet Quant Ratings

rates Rand Logistics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk and generally disappointing historical performance in the stock itself. Get the full

Rand Logistics Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

NovaBay Pharmaceuticals (NBY) - FREE Research Report

Najafi Ramin, who is Chief Executive Officer at NovaBay Pharmaceuticals, bought 25,000 shares at $0.65 on Dec. 8, 2014. Following this transaction, the Chief Executive Officer owned 3.2 million shares meaning that the stake was boosted by 0.8% with the 25,000-share transaction.

The shares most recently traded at $0.66, up $0.01, or 1.52% since the insider transaction. Historical insider transactions for NovaBay Pharmaceuticals go as follows:

  • 4-Week # shares bought: 18,000
  • 4-Week # shares sold: 30,000
  • 12-Week # shares bought: 18,000
  • 12-Week # shares sold: 30,000
  • 24-Week # shares bought: 18,000
  • 24-Week # shares sold: 30,000

The average volume for NovaBay Pharmaceuticals has been 150,800 shares per day over the past 30 days. NovaBay Pharmaceuticals has a market cap of $32.9 million and is part of the health care sector and drugs industry. Shares are down 48.26% year-to-date as of the close of trading on Monday.

NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing product candidates for the therapeutic needs of anti-infective market. The company operates in four segments: Dermatology, Ophthalmology, Urology, and Wound Care. Currently, there are no analysts who rate NovaBay Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NBY - FREE

TheStreet Quant Ratings

rates NovaBay Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

NovaBay Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null